Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial

Torky, Haitham; Taha, Ahmed; Marie, Heba; El-Desouky, El-Sayed; Raslan, O; Moussa, Asem; Ahmad, Ammara; Abo-Louz, Ashraf; Zaki, Sherif Mohamed; Fares, Tamer; Eesa, Ahmed N

doi:10.1080/13697137.2017.1421924

Cited by 25 publications

(43 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Roshangar et al in their study found that injection of 1 IU/gr oxytocin could significantly increase the endometrial thickness in the rat after 48 hours [24] In the present study, all of the subjective symptoms of vaginal atrophy significantly improved in the and used 600 IU oxytocin gel or placebo to relief the vaginal atrophy and followed patients for one month. Their results showed that all subjective and objective symptoms of vaginal atrophy decreased significantly in the oxytocin group [18]. These results are similar to what we found in our study.…”

Section: Discussionsupporting

confidence: 92%

“…The role of oxytocin on vaginal atrophy was examined first by Al-Saqi et al, and they found that oxytocin is a useful means for reducing vaginal atrophy in postmenopausal women [17]. Recently another study examined the effect of oxytocin vaginal gel on vaginal atrophy and the results showed that oxytocin could significantly reduce the vaginal atrophy after 30 days of the intervention [18]. There are only a few studies that evaluated the impact of vaginal gel of oxytocin on vaginal atrophy that one of them followed participants for four weeks and the other for seven weeks.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

Zohrabi

Abedi

Ansari

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women. Methods: This was a randomized controlled trial that was conducted on 96 postmenopausal women who suffered from vaginal atrophy. The inclusion criteria were: literate women, age 40-60, at least one year passed from their last menstrual period or the level of FSH>40IU, monogamous women with the sexual relationship. Women in the intervention group, requested to use one applicator of 400 IU oxytocin gel per night and women in the placebo group used placebo each night. The subjective symptoms of vaginal atrophy, vaginal PH, maturation index were measured before and after the intervention. Results: The number of superficial cells was increased significantly in the oxytocin group compared to placebo (38.7±7.18 vs. 3.69±2.76, p=0.0001), while the number of parabasal cells was decreased significantly in the oxytocin compared to placebo after the intervention. The improvement of the maturation index was more dominant in the oxytocin group (increased from 7.76±4.68 to 52.48±7.54) in comparison to the placebo group (increased from 8.58±4.35 to 13.25±5.06). The PH of the vagina decreased significantly in the oxytocin group in comparison to the placebo group (p=0.0001). After eight weeks, 88.6% and 7.1% of women in the oxytocin and placebo groups did not show the severe symptoms of vaginal atrophy (p=0.001) Conclusion: The results of this study showed that eight weeks intervention with oxytocin vaginal gel (400 IU) could significantly improve the vaginal maturation index, subjective symptoms of vaginal atrophy and reduce the PH of the vagina. Using this medication in women who have a contraindication for hormone therapy is recommended.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

Zohrabi

Abedi

Ansari

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…A study assessed the effect of prostaglandin IU oxytocin gel or placebo to relief the vaginal atrophy and followed patients for one month. Their results showed that all subjective and objective symptoms of vaginal atrophy decreased significantly in the oxytocin group [18]. These results are similar to what we found in our study.…”

Section: Discussionsupporting

confidence: 92%

“…One of the limitations of this study is; we did not assess the level of blood estrogen of participants. However, other studies showed that oxytocin did not affect the blood estrogen level [18]. In this study because of financial constraints, we were not able to prepare disposable applicator and used one applicator to transfer oxytocin gel or placebo into vagina.…”

Section: Strengths and Limitations Of The Studymentioning

confidence: 95%

“…The role of oxytocin on vaginal atrophy was examined first by Al-Saqi et al, and they found that oxytocin is a useful means for reducing vaginal atrophy in postmenopausal women [17]. Recently another study examined the effect of oxytocin vaginal gel on vaginal atrophy and the results showed that oxytocin could significantly reduce the vaginal atrophy after 30 days of intervention [18]. There are only few studies that evaluated the impact of vaginal gel of oxytocin on vaginal atrophy that one of they followed participants for four weeks and the other for seven weeks.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

Abedi¹,

Zohrabi²,

Ansari³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women. Methods: This was a randomized controlled trial that was conducted on 96 postmenopausal women who suffered from vaginal atrophy. The inclusion criteria were: literate women, age 40-60, at least one year passed from their last menstrual period or the level of FSH>40IU, monogamous women with the sexual relationship. Women in the intervention group, requested to use one applicator of 400 IU oxytocin gel per night and women in the placebo group used placebo each night. The subjective symptoms of vaginal atrophy, vaginal PH, maturation index were measured before and after the intervention. Results: The number of superficial cells was increased significantly in the oxytocin group compared to placebo (38.7±7.18 vs. 3.69±2.76, p=0.0001), while the number of parabasal cells was decreased significantly in the oxytocin compared to placebo after the intervention. The improvement of the maturation index was more dominant in the oxytocin group (increased from 7.76±4.68 to 52.48±7.54) in comparison to the placebo group (increased from 8.58±4.35 to 13.25±5.06). The PH of the vagina decreased significantly in the oxytocin group in comparison to the placebo group (p=0.0001). After eight weeks, 88.6% and 7.1% of women in the oxytocin and placebo groups did not show the severe symptoms of vaginal atrophy (p=0.001) Conclusion: The results of this study showed that eight week intervention with oxytocin vaginal gel (400 IU) could significantly improve the vaginal maturation index, subjective symptoms of vaginal atrophy and reduce the PH of the vagina. Using this medication in women who have a contraindication for hormone therapy is recommended.

show abstract

-Phasic Model of xytocin (): A systematic conceptual review of oxytocin-related ERP research

Pehlivanoglu

Myers

Ebner

2020

Biological Psychology

View full text Add to dashboard Cite

Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial

Abstract: Oxytocin gel is useful in the restoration of the vaginal epithelium in cases of postmenopausal atrophic vaginitis. Further studies with a longer follow-up period are required to test the long-term effects of oxytocin as a treatment for vaginal atrophy.

Cited by 25 publications

References 12 publications

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

-Phasic Model of xytocin (): A systematic conceptual review of oxytocin-related ERP research

Contact Info

Product

Resources

About